Eli Lilly and Company $LLY Stake Increased by JSF Financial LLC

JSF Financial LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 12.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,116 shares of the company’s stock after purchasing an additional 125 shares during the period. JSF Financial LLC’s holdings in Eli Lilly and Company were worth $870,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of LLY. Precedent Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after acquiring an additional 39 shares in the last quarter. Family CFO Inc purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $54,000. Duquesne Family Office LLC raised its holdings in shares of Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after acquiring an additional 32,640 shares in the last quarter. Corient IA LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth $570,000. Finally, Emerald Advisors LLC raised its holdings in shares of Eli Lilly and Company by 60.8% during the second quarter. Emerald Advisors LLC now owns 1,021 shares of the company’s stock worth $796,000 after acquiring an additional 386 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on LLY. JPMorgan Chase & Co. cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Berenberg Bank reissued a “hold” rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $938.94.

Insider Buying and Selling

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 in the last quarter. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 2.5%

Eli Lilly and Company stock opened at $840.46 on Monday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $795.46 billion, a price-to-earnings ratio of 54.93, a PEG ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The company’s fifty day moving average price is $734.60 and its two-hundred day moving average price is $765.44.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 37.6% compared to the same quarter last year. During the same period last year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.